Agile Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Agile Therapeutics

07/11/2022 22:41

* Agile Therapeutics Inc  AGRX.OQ  reported a quarterly
adjusted
loss of 53 cents​​ per share for the quarter ended in September.
The mean expectation of two analysts for the quarter was for a
loss of 44 cents per share.
    * Revenue rose 133.3% to $3.00 million from a year ago;
analysts
expected $2.33 million. 
    * Agile Therapeutics Inc's reported EPS for the quarter was
a loss
of 53 cents​.
    * The mean earnings estimate of analysts had fallen by
about 51.7%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Agile Therapeutics Inc shares had fallen by 10.0% this
quarter and lost 98.6% so far this year.
    * The company reported a quarterly loss of $19.67 million.
    * Wall Street's median 12-month price target for Agile
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
7 at 10:41 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.44          -0.53          Missed
 Jun. 30 2022      -3.70          -2.71          Beat
                                  -3.78          
 Dec. 31 2021      -6.00          -8.00          Missed